Back to top

Tale of the Tape

Zacks Equity Research

Aerie Pharmaceuticals (AERI) in Focus: Stock Moves 6.8% Higher

AERI ESPR

Trades from $3
Read Full ArticleHide Full Article
Aerie Pharmaceuticals, Inc. (AERI - Free Report) was a big mover last session, as the company saw its shares rise by almost 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock has now gained over 36% since June 4.

This drug manufacturer has seen no estimate revision over the past 30 days and its Zacks Consensus Estimate remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Aerie Pharmaceuticals has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Some stocks in the same industry looking equally good include POZEN Inc. , Ariad Pharmaceuticals Inc. and Esperion Therapeutics, Inc. (ESPR - Free Report) . While POZEN holds a Zacks Rank #1 (Strong Buy), Ariad Pharmaceuticals and Esperion Therapeutics carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>



In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Aerie Pharmaceuticals, Inc. (AERI) - free report >>

Esperion Therapeutics, Inc. (ESPR) - free report >>